Skip to main content
. Author manuscript; available in PMC: 2014 Apr 14.
Published in final edited form as: Am J Nephrol. 2012 Jun 19;36(1):50–57. doi: 10.1159/000339285

Figure 2. Prevention of Iron Sucrose induced phagocytic dysfunction with desferrioxiamine in PMNs.

Figure 2

To exclude the possible effect of the complex carbohydrate shell from that of the elemental iron core of the drug, blood samples were simultaneously treated with iron sucrose and the iron chelator, desferrioxamine.